BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2024-07

185 industry Phase 2/3 trial readout(s) and 29 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2024-06 | 2024-08 →

FDA decision events

DateEventStatusCompanyDrugSource
2024-07-01Complete response lettercomplete responseAmneal EU, Ltd. AMRXCRL 2024-07-01: Amneal EU, Ltd. NDA 218345
2024-07-01FDA approvalapprovedVIFOR FRESENIUSVELPHOROApproved 2024-07-01: VELPHORO (NDA205109 SUPPL9)
2024-07-02FDA approvalapprovedELI LILLY CO LLYKISUNLAApproved 2024-07-02: KISUNLA (BLA761248 ORIG1)
2024-07-04Complete response letterapproved sinceSamsung Bioepis Co., Ltd.Pyzchiva (ustekinumab-ttwe) injectionCRL 2024-07-04: Samsung Bioepis Co., Ltd. BLA 761373/Original 2, BLA 761425/Original 2, BLA 761373, BLA 761425 (Pyzchiva (ustekinumab-ttwe) injection)
2024-07-05FDA approvalapprovedMERZ PHARMSXeominApproved 2024-07-05: Xeomin (BLA125360 SUPPL99)
2024-07-09FDA approvalapprovedARCUTIS ARQTZORYVEApproved 2024-07-09: ZORYVE (NDA215985 SUPPL7)
2024-07-10Complete response lettercomplete responseNovo Nordisk Inc. NVONNC0148-0287 injectionCRL 2024-07-10: Novo Nordisk Inc. BLA 761326 (NNC0148-0287 injection)
2024-07-11Complete response lettercomplete responseMEDRx USA, Inc.CRL 2024-07-11: MEDRx USA, Inc. NDA 215029
2024-07-11FDA approvalapprovedLONG GROVE PHARMSVASOPRESSIN IN SODIUM CHLORIDE 0.9%Approved 2024-07-11: VASOPRESSIN IN SODIUM CHLORIDE 0.9% (NDA217766 ORIG1)
2024-07-13FDA approvalapprovedWSM SUPPLIER LLCMEDICAL AIR USPApproved 2024-07-13: MEDICAL AIR, USP (NDA219709 ORIG1)
2024-07-15Complete response lettercomplete responseOrexo ABNaloxone hydrochloride nasal powder, °®CRL 2024-07-15: Orexo AB NDA 217433 (Naloxone hydrochloride nasal powder, °®)
2024-07-17FDA approvalapprovedPHATHOM PHARMACEUTICALS INC PHATVOQUEZNAApproved 2024-07-17: VOQUEZNA (NDA218710 ORIG1)
2024-07-18FDA approvalapprovedZYDUS LIFESCIENCESZITUVIMET XRApproved 2024-07-18: ZITUVIMET XR (NDA216778 ORIG1)
2024-07-19FDA approvalapprovedSAMSUNG BIOEPIS CO LTDEPYSQLIApproved 2024-07-19: EPYSQLI (BLA761340 ORIG1)
2024-07-22FDA approvalapprovedMILLICENT MFG PRFEMLYVApproved 2024-07-22: FEMLYV (NDA218718 ORIG1)
2024-07-22FDA approvalapprovedXIAMEN LP PHARM COOPIPZAApproved 2024-07-22: OPIPZA (NDA216655 ORIG1)
2024-07-22FDA approvalapprovedNOVARTIS NVSKISQALIApproved 2024-07-22: KISQALI (NDA209092 SUPPL19)
2024-07-24FDA approvalapprovedMIRUM MIRMLIVMARLIApproved 2024-07-24: LIVMARLI (NDA214662 SUPPL10)
2024-07-24FDA approvalapprovedBIOMARIN PHARM BMRNBRINEURAApproved 2024-07-24: BRINEURA (BLA761052 SUPPL14)
2024-07-25FDA AdComheldAstraZeneca UK Limited AZNAdCom 2024-07-25: Oncologic Drugs Advisory Committee - sBLA 761069/S-043
2024-07-25Complete response lettercomplete responseXspray Pharma AB“” (dasatinib) tabletsCRL 2024-07-25: Xspray Pharma AB NDA 216195 (“” (dasatinib) tablets)
2024-07-25FDA approvalapprovedSUN PHARM INDS INCLEQSELVIApproved 2024-07-25: LEQSELVI (NDA217900 ORIG1)
2024-07-26Complete response lettercomplete responseRB Health (US) LLCnaproxen sodium |), dextromethorphan hydrobromide (4, guaifenesin | @) extended-release (ER) tabletCRL 2024-07-26: RB Health (US) LLC NDA 217338 (naproxen sodium |), dextromethorphan hydrobromide (4, guaifenesin | @) extended-release (ER) tablet)
2024-07-26FDA approvalapprovedAMNEAL AMRXPOTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDEApproved 2024-07-26: POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE (NDA218343 ORIG1)
2024-07-26FDA approvalapprovedLUYE INNOMIND PHARMAERZOFRIApproved 2024-07-26: ERZOFRI (NDA216352 ORIG1)
2024-07-26FDA approvalapprovedALPHA COGNITION ACOGZUNVEYLApproved 2024-07-26: ZUNVEYL (NDA218549 ORIG1)
2024-07-29FDA approvalapprovedNOVITIUM PHARMATEZRULYApproved 2024-07-29: TEZRULY (NDA218139 ORIG1)
2024-07-30FDA approvalapprovedJANSSEN BIOTECHDARZALEX FASPROApproved 2024-07-30: DARZALEX FASPRO (BLA761145 SUPPL25)
2024-07-31FDA approvalapprovedJANSSEN BIOTECHDARZALEXApproved 2024-07-31: DARZALEX (BLA761036 SUPPL50)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2024-07 est.P2Emerald Health PharmaceuticalsNCT04166552 Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic SclerosisDiffuse Cutaneous Systemic Sclerosissuspended36
2024-07 est.P3Everstar Therapeutics LimitedNCT04176588 A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative ColitisModerately to Severely Active Ulcerative Colitisunknown341
2024-07 est.P1/P2Mural Oncology, IncNCT04592653 Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)Advanced Solid Tumoractive not recruiting78
2024-07 est.P2Sorrento Therapeutics, Inc.NCT04992247 Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary CompromiseCovid19withdrawn
2024-07 est.P1/P2iTeos Belgium SANCT05060432 Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid TumorsAdvanced Cancer; Lung Cancer; Head and Neck Cancer; Melanomaunknown153
2024-07 est.P3EMSNCT05144360 Efficacy and Safety of Atenas Association in the Treatment of Type II Diabetes Mellitus and HypertensionHypertension Associated; Type II Diabetes Mellituswithdrawn
2024-07 est.P3Inmunotek S.L.NCT05400811 Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/RhinoconjunctivitisHouse Dust Mite Allergy; Perennial Allergic Rhinitis; Allergic Rhinoconjunctivitis; Allergic Asthmaunknown400
2024-07 est.P2Shanghai Ark Biopharmaceutical Co., Ltd.NCT05424887 A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosisunknown105
2024-07 est.P1/P2Shanghai EpimAb Biotherapeutics Co., Ltd.NCT05498389 EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung CancerMetastatic Lung Non-Small Cell Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Stage IV Lung Cancunknown115
2024-07 est.P1/P2Shanghai AbelZeta Ltd.NCT05521802 A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple MyelomaMultiple Myelomarecruiting92
2024-07 est.P3Boryung Biopharma Co., Ltd.NCT05613127 To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrsHepatitis A; Hep Aunknown106
2024-07 est.P2Shanghai JMT-Bio Inc.NCT06089330 A Study of JMT101 in Patients With Metastatic Colorectal CancerMetastatic Colorectal Cancer (mCRC)unknown102
2024-07 est.P2Vanda Pharmaceuticals VNDANCT06296966 A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeDry Eyeunknown40
2024-07-01P1/P2Teva Branded Pharmaceutical Products R&D LLCNCT03215030 A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple MyelomaMultiple Myelomaterminated272
2024-07-01P3Prestige Biopharma Limited PBHNCT03390686 A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer PatientsLung Cancer; Non-small Cell Lung Canceractive not recruiting650
2024-07-01 est.P3Lupin Ltd.NCT04700046 Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2Myotonic Dystrophy Type 1 and Type 2withdrawn
2024-07-01P2Actinogen MedicalNCT05657691 Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)Major Depressive Disorder; MDD; Cognitive Impairmentcompleted167
2024-07-01P3Eli Lilly and Company LLYNCT05691712 A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 DiabetesDiabetes Type 2; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Disease; Endocrine Systecompleted257
2024-07-01 est.P2/P3KARE BiosciencesNCT05706454 Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID PneumoniaCOVID-19 Pneumonia; COVID-19 Respiratory Infectionunknown324
2024-07-01P2Immuron Ltd. IMRNNCT05933525 Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.Diarrhea; Travelers Diarrhea; Infectious Diarrheacompleted63
2024-07-02P2Novartis Pharmaceuticals NVSNCT04573920 Atrasentan in Patients With Proteinuric Glomerular DiseasesIgA Nephropathy; Focal Segmental Glomerulosclerosis; Alport Syndrome; Diabetic Kidney Disease; Diabeactive not recruiting103
2024-07-02P3Eli Lilly and Company LLYNCT04847557 A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialObesity; Heart Failure With Preserved Ejection Fraction (HFpEF)completed731
2024-07-02P3CelgeneNCT05214768 A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic GastroenteritisEosinophilic Gastroenteritiscompleted48
2024-07-02P2Novartis Pharmaceuticals NVSNCT05562934 An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.Resistant Hypertensioncompleted189
2024-07-02P1/P2K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.NCT05682170 Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML)terminated40
2024-07-02P2Gilead Sciences GILDNCT05729568 A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 InfectionHIV-1 Infectionactive not recruiting83
2024-07-02P1/P2GlaxoSmithKlineNCT05823974 A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older AdultsInfluenza, Humancompleted1275
2024-07-03P2Takeda TAKNCT02924272 Ixazomib Rollover StudyMultiple Myeloma; Lymphoma; Amyloidosiscompleted32
2024-07-03P3LEO PharmaNCT03587805 Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTENDAtopic Dermatitiscompleted1672
2024-07-03P3Jiangsu HengRui Medicine Co., Ltd.NCT03825744 Hetrombopag or Placebo in Treatment-Naive Severe Aplastic AnemiaSevere Aplastic Anemiacompleted240
2024-07-03P3Agios Pharmaceuticals, Inc. AGIONCT03853798 Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007Pyruvate Kinase Deficiencycompleted90
2024-07-03P2Revolution Medicines, Inc. RVMDNCT05054725 Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesNon-Small Cell Lung Cancercompleted47
2024-07-03P3Hangzhou Sciwind Biosciences Co., Ltd.NCT05680129 A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMT2DM; Type 2 Diabetes Mellituscompleted623
2024-07-03P2Invirsa, Inc.NCT06370039 Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye DiseaseDry Eye Diseasecompleted109
2024-07-04P2MacroGenics MGNXNCT05551117 A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsCastration-Resistant Prostatic Cancer; Androgen-Independent Prostatic Cancer; Androgen-Insensitive Pterminated192
2024-07-04P2Topas Therapeutics GmbHNCT05660109 A Study to Assess the Safety of TPM502 in Adults With Celiac DiseaseCeliac Diseasecompleted28
2024-07-04P1/P2Keymed Biosciences Co.LtdNCT06162507 Study of CM310 in Children Subjects With Moderate-to-severe Atopic DermatisAtopic Dermatitiscompleted24
2024-07-05P1/P2Cytovation ASNCT04260529 CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate AccumulationsAdvanced Solid Tumor Malignancycompleted60
2024-07-05P2Alexion Pharmaceuticals, Inc.NCT05019521 A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationGeographic Atrophyterminated365
2024-07-05P2AbbVie ABBVNCT05141006 Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)completed83
2024-07-05 est.P2Takeda TAKNCT05469802 A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy AdultsHealthy Volunteerswithdrawn
2024-07-05P3AMIpharm Co., Ltd.NCT06256445 Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin AreaHealthycompleted252
2024-07-05P3SPH-BIOCAD (HK) LimitedNCT07277179 Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing SpondylAnkylosing Spondylitiscompleted113
2024-07-08P3AstraZeneca AZNNCT04269200 Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial CancerEndometrial Neoplasmsactive not recruiting805
2024-07-08P1/P2PT. Prodia Stem Cell IndonesiaNCT04314661 Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for OsteoartrithisOsteoarthritis, Kneecompleted31
2024-07-08P3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT04687241 Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive MutationsNon-small Cell Lung Canceractive not recruiting192
2024-07-08P2Boehringer IngelheimNCT04978493 A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's DiseaseCrohn Diseaseterminated49
2024-07-08P2Day One Biopharmaceuticals, Inc.NCT04985604 Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid TumorsMelanoma; Solid Tumor; CRAF Gene Amplification; RAF1 Gene Amplification; BRAF Gene Fusion; BRAF Fusiterminated23
2024-07-08P2Treos Bio LimitedNCT05243862 Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.Colorectal Cancer Metastaticcompleted18
2024-07-08P3Aridis Pharmaceuticals, Inc.NCT05331885 A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2Ventilator Associated Pneumonia; Staphylococcus Aureusterminated24
2024-07-08 est.P2GlaxoSmithKlineNCT05340257 A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRSInfections, Bacterialwithdrawn
2024-07-08P3IpsenNCT05458856 Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the ProstateProstate Cancercompleted147
2024-07-09P1/P2Baxalta now part of ShireNCT03370172 A Study of BAX 888 in Male Adults With Severe Hemophilia AHemophilia Acompleted4
2024-07-09P2Navidea BiopharmaceuticalsNCT04078191 Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RARheumatoid Arthritisterminated20
2024-07-09P2/P3Merck Sharp & Dohme LLC MRKNCT04767373 Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)Respiratory Syncytial Virus Infectioncompleted3632
2024-07-09P2Alpine Immune Sciences Inc, A Subsidiary of VertexNCT04835441 ALPN-101 (Acazicolcept) in Systemic Lupus ErythematosusSystemic Lupus Erythematosuscompleted76
2024-07-09P1/P2Inozyme PharmaNCT05030831 Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXEATP-Binding Cassette Subfamily C Member 6 Deficiency; Pseudoxanthoma Elasticum; Generalized Arterialcompleted10
2024-07-09P2Eli Lilly and Company LLYNCT05063539 A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's DiseaseAlzheimer Diseasecompleted327
2024-07-09P3Navidea BiopharmaceuticalsNCT05246280 Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RARheumatoid Arthritisterminated169
2024-07-09P2Jiangsu vcare pharmaceutical technology co., LTDNCT05997927 Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic DermatitisModerate to Severe Atopic Dermatitiscompleted149
2024-07-10P3Kolon TissueGene, Inc.NCT03203330 A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the KneeDegenerative Osteoarthritisactive not recruiting535
2024-07-10P3Onconic Therapeutics Inc.NCT05448001 Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric UlcerGastric Ulcercompleted329
2024-07-10P2Neurocrine Biosciences NBIXNCT05545111 Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With SchizophreniaSchizophreniacompleted210
2024-07-11P1/P2Sangamo Therapeutics SGMOQNCT04817774 Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant RecipientsKidney Transplant Rejection; End Stage Renal Diseasecompleted26
2024-07-11 est.P1/P2Algenis SpANCT05052398 Proof of Principle Study Evaluating Gonyautoxins NEURO SERUM, on Chemotherapy-induced Peripheral NeuropathyChemotherapy-induced Peripheral Neuropathyunknown52
2024-07-11P2Rakuten Medical, Inc.NCT05182866 ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck CancerHead and Neck Cancer; Squamous Cell Carcinoma of Head and Neckunknown9
2024-07-11P3CelltrionNCT05385770 Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive SubjectsEssential Hypertensioncompleted890
2024-07-11P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT05870319 A Phase III Study of SKB264 for EGFR Mutant NSCLC PatientsNon-small Cell Lung Canceractive not recruiting376
2024-07-12P1/P2Fore BiotherapeuticsNCT02428712 A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid TumorsAdvanced Unresectable Solid Tumors; BRAF-mutated Tumorscompleted113
2024-07-12P2Vivoryon Therapeutics N.V.NCT03919162 A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early ADAlzheimer Diseaseterminated112
2024-07-12P2Janssen Research & Development, LLCNCT04172675 A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With HigUrinary Bladder Neoplasmscompleted107
2024-07-12P2/P3Regeneron Pharmaceuticals REGNNCT04206553 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous PemphigoidBullous Pemphigoidcompleted106
2024-07-12P3GlaxoSmithKlineNCT05281523 Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)Nasal Polypscompleted264
2024-07-12P3Vanda Pharmaceuticals VNDANCT05366855 Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPPGeneralized Pustular Psoriasisterminated42
2024-07-12P3Merck Sharp & Dohme LLC MRKNCT05722015 A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With MetastatiMetastatic Non-small Cell Lung Canceractive not recruiting377
2024-07-12P3CanSino Biologics Inc.NCT06131554 A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 YearsMeningococcal Meningitiscompleted1480
2024-07-12 est.P2Haisco Pharmaceutical Group Co., Ltd.NCT06490484 Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to PregabalinDiabetic Peripheral Neuropathic Painunknown90
2024-07-13P2Arvinas Inc. ARVNNCT05549505 A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryBreast Cancercompleted152
2024-07-13P2Gan and Lee Pharmaceuticals, USANCT06202079 A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes MellitusDiabetes Mellitus, Type 2completed179
2024-07-13P2Vincentage Pharma Co., LtdNCT06569355 A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese PopulationObesity; Overweightcompleted250
2024-07-15P3Sanofi SNYNCT04410978 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)Relapsing Multiple Sclerosiscompleted974
2024-07-15P2/P3LeonaBio LONANCT04488419 ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseaseAlzheimer Disease; Dementia of Alzheimer Typecompleted554
2024-07-15P2Seagen, a wholly owned subsidiary of PfizerNCT04539938 A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerHER2 Positive Breast Cancercompleted70
2024-07-15 est.P3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT04951635 A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung CancerNon-small Cell Lung Cancerrecruiting150
2024-07-15P3Viridian Therapeutics, Inc. VRDNNCT05176639 A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)Thyroid Eye Diseasecompleted113
2024-07-15P3Orca Biosystems, Inc.NCT05316701 Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesAcute Myeloid Leukemia; Acute Lymphoid Leukemia; Mixed Phenotype Acute Leukemia; Undifferentiated Leactive not recruiting187
2024-07-15P2Forma Therapeutics, Inc.NCT05568225 A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-Rterminated17
2024-07-15P2Technovalia, Pty LtdNCT05605470 Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in AdultsCOVID-19, SARS CoV 2 Infectioncompleted150
2024-07-15 est.P3Johnson & Johnson Consumer Inc. (J&JCI) JNJNCT05845008 A Multiple-Dose Safety Study of Fixed Combination of Acetaminophen/Naproxen Sodium in Adolescents With Orthodontic PainOrthodontic Painwithdrawn
2024-07-15P2Incyte Corporation INCYNCT05906628 Topical Ruxolitinib Evaluation in Chronic Hand EczemaHand Eczemacompleted186
2024-07-15P2Shanghai Haiyan Pharmaceutical Technology Co., Ltd.NCT06680466 A Phase Ⅱ Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal SurgeryPaincompleted179
2024-07-15P1/P2MindRank AI LtdNCT06778850 A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight ParticipantsOverweight and Obese Volunteerscompleted128
2024-07-16P2Pfizer PFENCT03061201 A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia AHemophilia Acompleted13
2024-07-16P3Sanofi SNYNCT04410991 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)Relapsing Multiple Sclerosiscompleted899
2024-07-16P2Santhera PharmaceuticalsNCT05185622 A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)Duchenne Muscular Dystrophycompleted54
2024-07-16P1/P2ModernaTX, Inc.NCT05972174 A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy AdultsInfluenzacompleted1504
2024-07-17P1/P2Incyte Corporation INCYNCT05222555 Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL PatientsDiffuse Large B Cell Lymphomaactive not recruiting53
2024-07-17P2Escient Pharmaceuticals, IncNCT05525520 Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing CholangitisPrurituscompleted62
2024-07-17P2Annexin Pharmaceuticals ABNCT05532735 Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein OcclusionRetinal Vein Occlusioncompleted16
2024-07-17P2Armata Pharmaceuticals, Inc. ARMPNCT05616221 Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary PseudomoNon-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infectioncompleted48
2024-07-17P1/P2Vaxcyte, Inc. PCVXNCT06151288 Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in AdultsPneumococcal Vaccinescompleted1015
2024-07-17P2Icosavax, Inc.NCT06481579 A Study of IVX-A12 in Adults ParticipantsHealthy Participantscompleted143
2024-07-18P1/P2PDC*line Pharma SASNCT03970746 Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLCNon Small Cell Lung Canceractive not recruiting73
2024-07-18P3Sun Pharmaceutical Industries, Inc.NCT05041803 European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia AreataAlopecia Areatacompleted407
2024-07-18P3Enzene Biosciences Ltd.NCT05405725 A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®Postmenopausal Osteoporosiscompleted504
2024-07-18P2CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT05551598 Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)Neuromyelitis Optica Spectrum Disordercompleted46
2024-07-18P2Keymed Biosciences Co.LtdNCT05715320 Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic DermatitisAtopic Dermatitiscompleted160
2024-07-18P2Huahui HealthNCT05861674 A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus InfectionChronic Hepatitis Delta Virus Infectioncompleted101
2024-07-18P3Novo Nordisk A/S NVONCT05878938 A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)Haemophilia A; Haemophilia A With Inhibitorscompleted61
2024-07-19P2Hoffmann-La RocheNCT04225715 A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis BHepatitis B, Chroniccompleted281
2024-07-19P3Eli Lilly and Company LLYNCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)Atopic Dermatitiscompleted1153
2024-07-19P1/P2AkesoNCT05505825 A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung CancerSCLC,Extensive Stagecompleted36
2024-07-19P3Eli Lilly and Company LLYNCT05662332 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (Type 2 Diabetes; T2Dcompleted795
2024-07-19P2Innovent Biologics (Suzhou) Co. Ltd.NCT05970978 A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With BiologicsPsoriasiscompleted152
2024-07-19P2Suven Life Sciences LimitedNCT06126497 Study Evaluating Safety and Efficacy of Ropanicant in MDD PatientsMajor Depressive Disordercompleted41
2024-07-19P1/P2Iovate Health Sciences International IncNCT06628596 Acute Effects of Paraxanthine on Energy and FocusCognition; Appetite; Mental Energy; Dietary Supplementcompleted25
2024-07-20P1/P2BayerNCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenSolid Tumors Harboring NTRK Fusionactive not recruiting154
2024-07-20P3Ignis Therapeutics (Suzhou) LimitedNCT06103825 A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the TreatmSleep Apnea, Obstructive; Excessive Daytime Sleepinesscompleted204
2024-07-20 est.P2Gan and Lee Pharmaceuticals, USANCT06256549 A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes MellitusType 2 Diabetesunknown272
2024-07-21P3Otsuka Beijing Research InstituteNCT05650320 To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with ADAtopic Dermatitis (AD)completed240
2024-07-22P3Biogen BIIBNCT04241068 A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221Alzheimer's Diseaseterminated1696
2024-07-22P2/P3Edesa Biotech Inc. EDSANCT04401475 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVCOVID-19; ARDSterminated278
2024-07-22P2/P3Regeneron Pharmaceuticals REGNNCT04695977 CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced MelanomaMelanoma; Advanced Melanoma; Metastatic Melanoma; Unresectable Melanomaterminated20
2024-07-22P2Amgen AMGNNCT05032066 A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosisterminated153
2024-07-22P3AstraZeneca AZNNCT05755932 Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy ParticipantsMucociliary Clearancecompleted35
2024-07-22P1/P2Beijing QL Biopharmaceutical Co.,LtdNCT07065032 A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)Type 2 Diabetescompleted27
2024-07-23P3GenSight BiologicsNCT03293524 Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 YearLeber Hereditary Optic Neuropathycompleted98
2024-07-23P2ImmuneOncia Therapeutics Inc.NCT04414163 A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal TypeExtranodal NK/T-cell Lymphoma, Nasal Type; Extranodal NK/T-cell Lymphomaactive not recruiting23
2024-07-23P3Haisco-USA Pharmaceuticals, Inc.NCT05486416 Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective SurgeryGeneral Anesthesiacompleted465
2024-07-23P2Amylyx Pharmaceuticals Inc. AMLXNCT05676034 AMX0035 in Adult Patients With Wolfram SyndromeWolfram Syndromeactive not recruiting12
2024-07-23P2LifeSeasons Inc.NCT06672094 A Study to Investigate the Safety and Efficacy of NeuroQ on Cognitive Function in Health Adults with Self-Reported Memory ProblemsHealthy; Self-reported Memory Problemscompleted40
2024-07-24P1/P2Vaccinex Inc. VCNXNCT04815720 Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckRecurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)completed49
2024-07-24P3AstraZeneca AZNNCT05104866 A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-PositiveBreast Canceractive not recruiting732
2024-07-24P2Fujian Akeylink Biotechnology Co., Ltd.NCT05637541 Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 TabletsChronic Hepatitis bcompleted90
2024-07-24P3ACELYRIN Inc.NCT05905783 Hidradenitis Suppurativa Study of IzokibepHidradenitis Suppurativaterminated258
2024-07-24P2Thirty Respiratory LimitedNCT06041919 Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With TuberculosisRifampicin Susceptible Pulmonary Tuberculosisterminated20
2024-07-25P1/P2Imunon IMNNNCT03393884 Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Canceractive not recruiting130
2024-07-25P3Merck Sharp & Dohme LLC MRKNCT03765918 Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-347Head and Neck Neoplasmsactive not recruiting714
2024-07-25P3Intra-Cellular Therapies, Inc.NCT04959032 Lumateperone for the Prevention of Relapse in Patients With SchizophreniaSchizophreniacompleted592
2024-07-25 est.P2Scarless Laboratories, Inc.NCT05501327 Dose Regimen Study of SLI-F06 in Healthy VolunteersScar; Wound Healingrecruiting30
2024-07-25 est.P2DermBiont, Inc.NCT06099080 A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)Dermatosis Papulosa Nigraunknown10
2024-07-26P2Lepu Biopharma Co., Ltd.NCT04868162 A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and NeckRecurrent or Metastatic Squamous Cell Carcinoma of Head and Neckcompleted70
2024-07-26P3Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USANCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)Pulmonary Arterial Hypertensioncompleted173
2024-07-26P2ModernaTX, Inc.NCT04917861 A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus AreasZika Viruscompleted808
2024-07-26P2StemCyte, Inc.NCT05682560 Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID SyndromeLong COVID; Post-COVID Syndrome; Post COVID-19 Conditioncompleted30
2024-07-26P3PharmaEssentia Japan K.K.NCT06002490 A Study to Evaluate P1101 in Japanese PV PatientsPolycythemia Vera (PV)completed21
2024-07-27P2KinoPharma Inc.NCT05896215 OM202JP Clinical Study of KNP2002Common Wartcompleted159
2024-07-29P1/P2Dizal PharmaceuticalsNCT03974022 Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Non-Small Cell Lung Canceractive not recruiting315
2024-07-29P3Hoffmann-La RocheNCT05091567 A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage SmalSmall-Cell Lung Canceractive not recruiting660
2024-07-29P3Dompé Farmaceutici S.p.ANCT05254990 Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired PneumoniaInfectious Pneumonia; Severe COVID-19terminated414
2024-07-29P2AstraZeneca AZNNCT05941897 A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung CanceAdvanced or Metastatic NSCLCactive not recruiting39
2024-07-29P3Janssen Research & Development, LLCNCT06095115 A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque PsoriasisPlaque Psoriasisactive not recruiting684
2024-07-29P2BayerNCT06195930 A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection FractionChronic Heart Failure With Reduced Ejection Fractioncompleted106
2024-07-29P3GlaxoSmithKlineNCT06389487 A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for RespiRespiratory Syncytial Virus Infectionscompleted1459
2024-07-30 est.P2Stemedica Cell Technologies, Inc.NCT02833792 Allogeneic Human Mesenchymal Stem Cells for Alzheimer's DiseaseAlzheimer Dementiaunknown40
2024-07-30 est.P3Techfields Pharma Co. LtdNCT03110523 A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Lumbar SpineOsteoarthritis of the Lumbar Spine; Pain, Backwithdrawn
2024-07-30 est.P2Kuros Biosurgery AGNCT04294004 KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody FusionDegenerative Disc Disease; Spinal Fusionunknown50
2024-07-30P2Provention Bio, a Sanofi CompanyNCT04424927 PRV-015 in Gluten-free Diet Non-responsive Celiac DiseaseCeliac Diseasecompleted388
2024-07-30P1/P2Olema Oncology, Inc. OLMANCT04505826 A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast CancerHormone Receptor Positive Breast Carcinoma; HER2-negative Breast Cancercompleted153
2024-07-30 est.P1/P2Ascentage Pharma Group Inc. AAPGNCT04964518 A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)AML, Adultunknown24
2024-07-30P2SonALAsense, Inc.NCT05123534 A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPGDiffuse Intrinsic Pontine Glioma; Diffuse Midline Gliomasuspended15
2024-07-30 est.P3Beijing InnoCare Pharma Tech Co., Ltd.NCT05234684 A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)unknown150
2024-07-30P3Eli Lilly and Company LLYNCT05260021 A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or BasType2 Diabetes; Diabetes Mellitus; Diabetes Mellitus, Type 2; T2D; T2DM (Type 2 Diabetes Mellitus); completed99
2024-07-30P3GlaxoSmithKlineNCT05274750 Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal PolypsNasal Polypscompleted276
2024-07-30 est.P1/P2BioNova Pharmaceuticals (Shanghai) LTD.NCT05365100 A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHLCLL/SLL; NHLwithdrawn
2024-07-30P2Priovant Therapeutics, Inc.NCT05523765 A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior UveitisNon-infectious Intermediate Uveitis; Non-infectious Posterior Uveitis; Non-infectious Pan Uveitiscompleted26
2024-07-30P3CSPC Ouyi Pharmaceutical Co., Ltd.NCT05707832 A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive AspergillusInvasive Candidiasis; Invasive Aspergillosiscompleted31
2024-07-30P3PainReform LTDNCT05773846 A Study to Evaluate Analgesic Efficacy and Safety of PRF-110 for Post-surgical PainBunioncompleted428
2024-07-31 est.P2/P3RemeGen Co., Ltd.NCT03500380 A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver MetastasesBreast Neoplasms; Breast Diseases; Capecitabine; HER2-positive Breast Cancer; HER2 Positive Breast Cunknown301
2024-07-31P1/P2Karyopharm Therapeutics Inc KPTIQNCT04256707 Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability andNon-Small Cell Lung Carcinoma (NSCLC); Colorectal Cancer (CRC); Other Solid Tumorscompleted80
2024-07-31P2Seagen, a wholly owned subsidiary of PfizerNCT04430738 Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersColorectal Carcinoma; Gastric Adenocarcinoma; GEJ Adenocarcinoma; Esophageal Adenocarcinoma; Cholangactive not recruiting40
2024-07-31P2Humanetics CorporationNCT04482595 BIO 300 Oral Suspension in Previously Hospitalized Long COVID PatientsCOVID-19; Long COVID; Pulmonary Fibrosis; Post-acute Respiratory Complications of COVID-19unknown50
2024-07-31P2AEON Biopharma, Inc. AEONNCT05016661 Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine PreventionMigraineterminated466
2024-07-31P2Haihe Biopharma Co., Ltd.NCT05043922 A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell CarcinomaOvarian Cancer; Recurrent Canceractive not recruiting93
2024-07-31P3Enimmune CorporationNCT05099029 A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and ChildrenEnterovirus Infectionscompleted3982
2024-07-31 est.P2Genentech, Inc.NCT05129423 A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous UrticariaChronic Spontaneous Urticariawithdrawn
2024-07-31P1/P2TriSalus Life Sciences, Inc. TLSINCT05220722 Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver TumorsHepatocellular Carcinoma; Intrahepatic Cholangiocarcinomaterminated23
2024-07-31 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05300269 SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal CancerLocally Advanced Rectal Cancerunknown73
2024-07-31P2Hutchison Medipharma LimitedNCT05509699 Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung CancerExtensive-Stage Small Cell Lung Cancercompleted21
2024-07-31P3Acrotech Biopharma Inc.NCT05571943 A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic DermatitisAtopic Dermatitiscompleted542
2024-07-31 est.P3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05715840 Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or MetRecurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)unknown368
2024-07-31 est.P2Hansoh BioMedical R&D CompanyNCT06077331 A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque PsoriasisPsoriasisunknown120
2024-07-31P2Valneva Austria GmbHNCT06106581 A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 YearsChikungunya Virus Infectioncompleted304
2024-07-31P2Escient Pharmaceuticals, IncNCT06144424 Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic DermatiAtopic Dermatitiscompleted32
2024-07-31 est.P3WestVac Biopharma Co., Ltd.NCT06175494 A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 COVID-19unknown4800

← 2024-06 | 2024-08 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.